A renal variant of fabry disease: A case with a novel gal a hemizygote mutation

Journal of Nephropathology

Volumn 1, Issue 3, 2012, Pages 194-197

  Mukdsi, Jorge H ^a   Gutiérrez, Silvina ^a   Barrón, Belén ^b   Novoa, Pablo ^b   Fernández, Segundo ^c   de Diller, Ana B ^d   Torres, Alicia I ^a   Formica, Richard N ^e   Orías, Marcelo ^b  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^b Sanatorio Allende   (Argentina)

^c CIPERCA Centro de Diálisis   (Argentina)

^d HOSPITAL PRIVADO   (Argentina)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Enzyme replacement therapy; Fabry disease; Kidney electron microscopy

Indexed keywords

EID: 84867407858     PISSN: 22518363     EISSN: 22518819     Source Type: Journal    
DOI: 10.5812/nephropathol.8123     Document Type: Article

References (10)

1. Oqvist B, Brenner BM, Oliveira JP, Ortiz A, Schaefer R, Svarstad E, et al. Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations. Nephrol Dial Transplant. 2009;24(6):1736-43.
2. Lee NC, Niu DM, Lin CY, Hsiao KJ, Yang AH, Ng YY. Alpha-galactosidase activity should be examined in patients with proteinuria: what have we learned from a family affected with Fabry disease? Nephrol Dial Transplant. 2006;21(2):549-50.
3. Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, et al. Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int. 2003;64(3):801-7.
4. Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, et al. Natural history of Fabry renal disease: influence of alpha-galactosidaseA activity and genetic mutations on clinical course. Medicine (Baltimore). 2002;81(2):122-38.
5. Winchester B, Young E. Biochemical and genetic diagnosis of Fabry disease. Fabry Disease: Perspectives from 5 Years of FOS, Oxford Pharma Genesis Ltd. In: Mehta A, Beck M, Sunder-Plassmann G, editor(s). p. 169-181.
6. Ortiz A, Oliveira JP, Wanner C, Brenner BM, Waldek S, Warnock DG. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults. Nat Clin Pract Nephrol. 2008;4(6):327-36.
7. Liu FL, Cohen RD, Downar E, Butany JW, Edelson JD, Rebuck AS. Amiodarone toxicity: Functional and ultrastructural evaluation. Thorax. 1986;41(2):100-5.
8. Albay D, Adler SG, Philipose J, Calescibetta CC, Romansky SG, Cohen AH. Chloroquine-induced lipidosis mimicking Fabry disease. Mod Pathol. 2005;18(5):733-8.
9. Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. 2002;62(6):1933-46.
10. Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 2007;18(5):1547-57.